Oncimmune (ONC) Competitors GBX 15.08 +0.28 (+1.89%) (As of 12/20/2024 06:06 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider Trades ONC vs. SBTX, TRX, POLB, COS, C4XD, DDDD, SAR, AREC, OKYO, and OPTIShould you be buying Oncimmune stock or one of its competitors? The main competitors of Oncimmune include SkinBioTherapeutics (SBTX), Tissue Regenix Group (TRX), Poolbeg Pharma (POLB), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), Sareum (SAR), Arecor Therapeutics (AREC), OKYO Pharma (OKYO), and OptiBiotix Health (OPTI). These companies are all part of the "biotechnology" industry. Oncimmune vs. SkinBioTherapeutics Tissue Regenix Group Poolbeg Pharma Collagen Solutions plc (COS.L) C4X Discovery 4D pharma Sareum Arecor Therapeutics OKYO Pharma OptiBiotix Health Oncimmune (LON:ONC) and SkinBioTherapeutics (LON:SBTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings, community ranking and media sentiment. Which has more risk and volatility, ONC or SBTX? Oncimmune has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, SkinBioTherapeutics has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500. Is ONC or SBTX more profitable? Oncimmune has a net margin of 586.08% compared to SkinBioTherapeutics' net margin of 0.00%. SkinBioTherapeutics' return on equity of -118.63% beat Oncimmune's return on equity.Company Net Margins Return on Equity Return on Assets Oncimmune586.08% -760.96% -26.38% SkinBioTherapeutics N/A -118.63%-61.18% Does the MarketBeat Community favor ONC or SBTX? Oncimmune received 21 more outperform votes than SkinBioTherapeutics when rated by MarketBeat users. However, 60.26% of users gave SkinBioTherapeutics an outperform vote while only 59.13% of users gave Oncimmune an outperform vote. CompanyUnderperformOutperformOncimmuneOutperform Votes6859.13% Underperform Votes4740.87% SkinBioTherapeuticsOutperform Votes4760.26% Underperform Votes3139.74% Which has preferable valuation and earnings, ONC or SBTX? SkinBioTherapeutics has lower revenue, but higher earnings than Oncimmune. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Oncimmune, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncimmune£1.21M9.24-£3.14M-£0.03-502.67SkinBioTherapeutics£21.95K1,727.94-£2.88M-£0.02-838.75 Does the media favor ONC or SBTX? In the previous week, Oncimmune's average media sentiment score of 0.00 equaled SkinBioTherapeutics'average media sentiment score. Company Overall Sentiment Oncimmune Neutral SkinBioTherapeutics Neutral Do institutionals & insiders believe in ONC or SBTX? 25.0% of Oncimmune shares are held by institutional investors. Comparatively, 16.6% of SkinBioTherapeutics shares are held by institutional investors. 31.0% of Oncimmune shares are held by insiders. Comparatively, 20.4% of SkinBioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryOncimmune beats SkinBioTherapeutics on 7 of the 13 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Oncimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONC vs. The Competition Export to ExcelMetricOncimmuneBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£11.18M£165.68M£5.14B£1.90BDividend YieldN/A3.64%5.09%5.45%P/E Ratio-502.67115.5190.131,863.09Price / Sales9.2418,531.021,116.25392,686.74Price / Cash11.9612.8743.1028.61Price / BookN/A8.594.782.80Net Income-£3.14M-£20.67M£120.31M£155.77M7 Day Performance-3.64%-1.05%-1.92%-2.02%1 Month Performance-5.16%174.77%13.65%21.64%1 Year Performance-44.15%134.18%28.34%29.70% Oncimmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCOncimmuneN/AGBX 15.08+1.9%N/A-41.3%£11.18M£1.21M-502.6752SBTXSkinBioTherapeuticsN/AGBX 19.13+2.0%N/A+6.5%£43.24M£21,949.00-956.2511TRXTissue Regenix GroupN/AGBX 59.50+2.6%N/A+6.8%£42.38M£31.80M-5,950.00120News CoveragePOLBPoolbeg PharmaN/AGBX 7.37+2.4%N/A-23.2%£36.85MN/A-737.0012Gap UpCOSCollagen Solutions plc (COS.L)N/AGBX 6.63flatN/A+0.0%£30.99M£4.01M-8.283,350C4XDC4X DiscoveryN/AN/AN/AN/A£30.27M£24.68M300.0049High Trading VolumeDDDD4D pharmaN/AN/AN/AN/A£30.05M£718,000.00-1.08106News CoverageSARSareumN/AGBX 27+1.9%N/A-51.7%£29.15M£47,204.00-450.003,211ARECArecor TherapeuticsN/AGBX 70-0.7%N/A-63.3%£26.43M£4.90M-250.0010Gap DownOKYOOKYO PharmaN/AGBX 1.40-24.3%N/AN/A£23.24MN/A-140.007News CoverageGap DownOPTIOptiBiotix HealthN/AGBX 22.60+6.6%N/A-26.9%£22.13M£1.26M-753.331High Trading Volume Related Companies and Tools Related Companies SBTX Alternatives TRX Alternatives POLB Alternatives COS Alternatives C4XD Alternatives DDDD Alternatives SAR Alternatives AREC Alternatives OKYO Alternatives OPTI Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:ONC) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncimmune Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
